The Food and Drug Administration stopped enrollment on a clinical trial evaluating LN-145 TIL for non-small cell lung cancer after a patient on the trial died.
The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.